Showing 4761-4770 of 5646 results for "".
- HelpMeSee Names Saro Jahani As President and CEOhttps://modernod.com/news/helpmesee-names-saro-jahani-as-president-and-ceo/2478266/Nonprofit HelpMeSee announced the appointment of Saro Jahani as President and CEO. He will also join the Board of Directors. Mr. Jahani succeeds Jacob Mohan Thazahathu, who retired after 10 years of service. Mr. Jahani
- Study to Investigate If Those With Diabetic Eye Disease Are At Greater Risk of COVID-19 Complicationshttps://modernod.com/news/study-to-investigate-if-those-with-diabetic-eye-disease-are-at-greater-risk-of-covid-19-complications/2478267/Fight for Sight is partnering with Diabetes UK to investigate if people with diabetic retinopathy are at greater risk of developing complications from COVID-19, in a study that hopes to save lives. This research, which will be carried out at the University of Edinburgh, will investigate wh
- The Vision Council Launches New Brand Identity and Member-Focused Websitehttps://modernod.com/news/the-vision-council-launches-new-brand-identity-and-member-focused-website/2478260/The Vision Council announced the launch of a new brand identity, including a reimagined logo and a new website designed to better serve and accommodate the needs of members and the vision care community at large. The rebrand and website launch represent the initial phase of the plan The Vision Co
- Regenxbio Announces Dosing of First Patient in Phase 2 AAVIATE Trial of RGX-314 for the Treatment of Wet AMDhttps://modernod.com/news/regenxbio-announces-dosing-of-first-patient-in-phase-2-aaviate-trial-of-rgx-314-for-the-treatment-of-wet-amd/2478257/Regenxbio announced that the first patient has been dosed in the AAVIATE trial, a phase 2 trial to evaluate the suprachoroidal delivery of RGX-314 using the SCS Microinjector for the treatment of wet age-related macular degeneration (AMD). The company expects to report interim data from the first
- Orbis International Announces New CEO & Presidenthttps://modernod.com/news/orbis-international-announces-new-ceo-president/2478251/Orbis International announced the appointment of Derek Hodkey as the organization’s new CEO and President, with immediate effect, following the retirement of Bob Ranck, who led Orbis for over 4 years.
- Independent, Smaller Hospitals Will Need to Make Tough Choices to Survive COVID-19 Financial Crisis: Analysishttps://modernod.com/news/independent-smaller-hospitals-will-need-to-make-tough-choices-to-survive-covid-19-financial-crisis-analysis/2478252/Independent hospitals could need to make drastic decisions such as reducing service lines or workforces to survive the cash crisis caused by the COVID-19 pandemic, a new analysis finds, according to a FierceHealthcare
- BVI Expands Malosa Single-Use Instrument Range in the UShttps://modernod.com/news/bvi-expands-malosa-single-use-instrument-range-in-the-us/2478253/BVI announced the extension of its Malosa range of single-use ophthalmic instruments in the US. The US Malosa portfolio will now include specialty instruments for use in corneal refractive surgery, complementing the existing single-use product range for cataract, oculoplastic, and office-based pr
- Liminal BioSciences Announces Resubmission of Biologics License Application to FDA for Ryplazimhttps://modernod.com/news/liminal-biosciences-announces-resubmission-of-biologics-license-application-to-fda-for-ryplazim/2478254/Liminal BioSciences announced that the company, through its U.S. subsidiary Prometic Biotherapeutics, has filed a resubmission of the biologics license application (BLA) for Ryplazim (plasminogen) (Ryplazim) with the FDA for the treatment of congenital plasminogen deficiency (C-PLGD). “The
- Saliva COVID-19 Test as Good as, Perhaps Beats, Nasal Swab: Studyhttps://modernod.com/news/saliva-covid-19-test-as-good-as-perhaps-beats-nasal-swab-study/2478248/A COVID-19 saliva test protocol developed by researchers at Yale University appeared to perform at least as well as nasal swabs in a study of hospital patients, a finding that may help encourage more frequent use of self-collected samples, according to a Medscape
- CEO Expects Pfizer Will Know By October If COVID-19 Vaccine Workshttps://modernod.com/news/ceo-expects-pfizer-will-know-by-october-if-covid-19-vaccine-works/2478246/Pfizer CEO Albert Bourla said that late-stage study results could be available by the end of October for a coronavirus vaccine it is co-developing with BioNTech, adding “we should have enough [data]…to say whether the product works or not.” His remarks come in the wake of the Trump ad